Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Trial details
- Registry ID
- NCT05714345
- Phase
- Phase 2
The FDA approved Fludarabine (Fludara®) on 18 Apr 1991.
Drug identity checked against registry records
Also recorded as Fludara®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyNCT05714345 | Allogene Therapeutics | Phase 2 | Terminated | 2024-02-20Actual |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514 | Actinium Pharmaceuticals | Phase 2, Phase 3 | Not yet recruiting | 2029-02Estimated |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.NCT06319456 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-08Estimated |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273 | Allogene Therapeutics | Phase 2 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1991-04-18Day | Fludarabine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020038", "applicant_as_listed_by_fda": "GENZYME CORP", "brand_names": ["FLUDARA"], "active_ingredients": ["FLUDARABINE PHOSPHATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19910418", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |